RonanRX (YC S26) – Personalized Peptides and GLP-1s
Hi HN,I’m Lloyd, one of two founders of RonanRx (https://ronanrx.com/). We are building a vertically integrated pharmaceutical company with software for prescribing, telehealth, compounding, manufacturing, and delivery. We are starting with GLP-1s and peptides.The path to RonanRx is fairly unconventional. During the pandemic, I built one of the largest mask manufacturing factories in the US. We could make a million masks in a day. We converted raw polypropylene pellets into finished pallets of masks.I had a background in software from my YC W10 company, so we took a software approach to building our factory. We used machine learning and computer vision to optimize production. We also vertically integrated almost everything. It worked. We built an efficient manufacturing operation and grew the business to 50 million dollars in revenue. Then people actually stopped caring about masks. Fair enough.Around the same time, I decided to try and lose the weight I had gained while building the factory. I ate nothing but chicken for six months. While this diet got some results, I plateaued. My doctor suggested tirzepatide, a GLP-1 medication.For me, losing weight was only the beginning. "Food noise" was gone. I showed less interest in other compulsive behavior. I stopped scrolling Instagram and quit biting my nails. But that was just the beginning. I was born with a congenital heart defect called aortic stenosis. My whole life doctors told me I'd need open heart surgery in my 40s (I am 45 now). After just 18 months using tirzepatide, my cardiologist’s began to think (and still thinks) my surgery could be pushed back until I am 70 or 80.This was all happening when I was deciding what to work on next. I wanted to keep working on manufacturing. I didn't want to build another product that could be replicated by a frontier model. Pharmaceutical manufacturing was the best combination of digital, physical, biological, and regulatory infrastructure I
FL score
out of 100
Verdict
medium confidence
Competition
No competitor data yet
Trend
No signal yet
Vertically integrated pharmaceutical manufacturing for GLP-1s and peptides, leveraging software optimization and direct-to-consumer distribution to undercut incumbent pricing and improve access.
The pain
The gap
Build angle
Strengths
- Founder has direct manufacturing operations experience at scale, not just theory
- Personal health outcome creates authentic founder-market fit and long-term commitment
- GLP-1 market is massive ($100B+ TAM), growing, and supply-constrained, not a niche
- Vertical integration + software is defensible; hard to replicate without both pieces
- YC S26 backing signals institutional validation and network access
- Regulatory moat protects against AI/software-only competitors
Risks
- Pharmaceutical manufacturing is capital-intensive; compounding margins may not fund transition to full manufacturing
- FDA approval timelines are 5-10 years; business must survive on compounding revenue alone
- Incumbent pharma (Novo Nordisk, Eli Lilly) have pricing power and distribution; price competition may be harder than expected
- Telehealth + pharma is crowded (Ro, Hims, Amazon Pharmacy); differentiation must be real, not just marketing
- Supply chain for raw peptides/GLP-1 precursors is controlled by few suppliers; vertical integration may hit bottlenecks
- Founder's previous success was in a commodity (masks); pharma requires different regulatory and clinical expertise
- Personal health story is compelling but not a business model; execution risk is high
Fly Labs Method
Is the pain real, is there a gap, is it the right time, can one person build it.
Value Equation
Dream outcome and how likely it feels, against the time and effort it costs.
One-Person Business
Curiosity pull, identity fit, and a path from free value to paid for a solo creator.
Viral Frameworks
Hook strength, shareability, and how cheaply it can be tested.
Builder Lens
Evidence the problem exists, timing, defensibility, and a model that fits on a napkin.
Five lenses, one composite. How scoring works
The angle
No market research recorded for this idea yet.
Semble – Code search for agents that uses 98% fewer tokens than grep
Hey HN! We (Stephan and Thomas) recently open-sourced Semble. We kept running into the same problem while using Claude Code on large codebases: when the agent can't find something directly, it falls back to grep, reading full files or launching subagents. This uses a lot of tokens, and often still misses the relevant code. There are existing tools for this, but they were either too slow to index on demand, needed API keys, or had poor retrieval quality.Semble is our solution for this. It combines static Model2Vec embeddings (using our latest static model: potion-code-16M) with BM25, fused via RRF and reranked with code-aware signals. Everything runs on CPU since there's no transformers involved. On our benchmark of ~1250 query/document pairs across 63 repos and 19 languages, it uses 98% fewer tokens than grep+read and reaches 99% of the retrieval quality of a 137M-parameter code-trained transformer, while being ~200x faster.Main features:- Token-efficient: 98% fewer tokens than grep+read- Fast: ~250ms to index a typical repo on our benchmark, ~1.5ms per query on CPU (very large repos may take longer)- Accurate: 0.854 NDCG@10, 99% of the best transformer setup we tested- MCP server: drop-in for Claude Code, Cursor, Codex, OpenCode- Zero config: no API keys, no GPU, no external servicesInstall in Claude Code with: claude mcp add semble -s user -- uvx --from "semble[mcp]" sembleOr check our README for other installation instructions, benchmarks, and methodology:Semble: https://github.com/MinishLab/sembleBenchmarks: https://github.com/MinishLab/semble/tree/main/benchmarksModel: https://huggingface.co/minishlab/potion-code-16MLet us know if you have any feedback or questions!
AI
Postgres extension for BM25 relevance-ranked full-text search
Last summer we faced a conundrum at my company, Tiger Data, a Postgres cloud vendor whose main business is in timeseries data. We were trying to grow our business towards emerging AI-centric workloads and wanted to provide a state-of-the-art hybrid search stack in Postgres. We'd already built pgvectorscale in house with the goal of scaling semantic search beyond pgvector's main memory limitations. We just needed a scalable ranked keyword search solution too.The problem: core Postgres doesn't provide this; the leading Postgres BM25 extension, ParadeDB, is guarded behind AGPL; developing our own extension appeared daunting. We'd need a small team of sharp engineers and 6-12 months, I figured. And we'd probably still fall short of the performance of a mature system like Parade/Tantivy.Or would we? I'd be experimenting long enough with AI-boosted development at that point to realize that with the latest tools (Claude Code + Opus) and an experienced hand (I've been working in database systems internals for 25 years now), the old time estimates pretty much go out the window.I told our CTO I thought I could solo the project in one quarter. This raised some eyebrows.It did take a little more time than that (two quarters), and we got some real help from the community (amazing!) after open-sourcing the pre-release. But I'm thrilled/exhausted today to share that pg_textsearch v1.0 is freely available via open source (Postgres license), on Tiger Data cloud, and hopefully soon, a hyperscalar near you:https://github.com/timescale/pg_textsearchIn the blog post accompanying the release, I overview the architecture and present benchmark results using MS-MARCO. To my surprise, we were not only able to meet Parade/Tantivy's query performance, but exceed it substantially, measuring a 4.7x advantage on query throughput at scale:https://www.tigerdata.com/blog/pg-textsearch-bm25-fu
AI
Consus (YC F24) – LLM gateway for companies handling sensitive data
Hey Hacker News! I'm Eric, the founder of Consus. We route all AI requests to ITAR restricted and controlled unclassified information (CUI) compliant infrastructure. Consus itself satisfies ITAR restrictions, and we recently completed our FedRAMP equivalency audit against the 410 FedRAMP High controls. FedRAMP High is the U.S. government’s strictest security baseline for cloud services handling sensitive unclassified data. A breach of this data could cause severe or catastrophic harm. Achieving FedRAMP equivalency, or authorization, is required before processing CUI information.Demo: https://youtu.be/6MYxJe6P4oYAerospace and defense is experiencing rapid growth. Unfortunately, most companies are struggling to use AI because of necessary data protections & compliance risk. These companies can move even faster if they could use the AI tools that most other industries take for granted.I spent most of my career prior to Consus in aerospace & defense. I launched national security payloads at SpaceX, and was an early employee at Castelion. I’ve watched first hand how compliance red-tape makes it difficult for companies to adopt new technologies and trust vendors that touch their sensitive data. For example, I worked with a satellite manufacturer that doesn’t allow any AI tools, even for non-sensitive work.Even as AI has become extremely useful over the past 9-12 months, I was surprised by how many aerospace & defense companies refused to touch it. They could see how it could be helpful, but they were scared about model providers training on their data, violating an ITAR rule, or risk losing new business because of a failed cyber assessment. These are all rational fears.There were a lot of ways to solve some/all of these problems, but we focused on building a compliant AI inference layer that can "plug" into any AI tool or workflow. Just as OpenRouter integrates with most tools, Consus can connect to tools like ChatGPT or Clau
AI
Questions about this idea?
FlyBot reads the scoring and gives you a second opinion on “RonanRX (YC S26) – Personalized Peptides and GLP-1s”.